Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test
Trial details
- Registry ID
- NCT05282797
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge TestNCT05282797 | Anebulo Pharmaceuticals | Phase 2 | Completed | 2023-08-26Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |